MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorNader Pouratian

About this trial

This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer. This technology is named MindEx (for Mind Extender). It utilizes four implanted "chips" in the human brain from which investigators can record brain activity during subjects' thoughts and decode meaningful information from this activity to be used as control signals for a computer, a laptop, or a tablet. The use of four brain regions is a significant differentiating feature and scientific innovation of this study over much prior work in this space, that typically derived control signals from one, or sometimes two brain regions. The brain regions to be used here can allow the decode of multiple variables simultaneously, including not just moment-to-moment position, but also high-level goals, intentions, decisions, scene comprehension, and error-related signals involved in natural human behavior. The research is being done through a prospective, longitudinal, single-arm early feasibility study to examine the safety and effectiveness of using MindEx to provide the user an intuitive, efficient, and accurate ability to control multiple applications on a computer interface such as a word processor, a paint application, or to play simple video games. Such versatility could greatly improve the autonomy and quality of life of severely paralyzed individuals. Two subjects will be enrolled, each implanted with MindEx for a period of at least 53 weeks and up to 313 weeks. The study is expected to take at least one year and up to six years in total.

Eligibility criteria

Qualifiers

Paralysis resulting from cervical spinal cord injury (SCI), brainstem stroke (ischemic or hemorrhagic), or amyotrophic lateral sclerosis (ALS)

Provide informed consent

Understand and comply with instructions, if necessary, with the aid of a translator

Communicate via speech or other means

Disqualifiers

Presence of memory problems

Intellectual impairment

Psychotic illness or chronic psychiatric disorder, including major depression if untreated

Poor visual acuity

Trial design

Treatments tested in this trial

  • Mind Extender (MindEx)

Treatment groups

2 Participants
are divided into 1 treatment group

Sponsors and collaborators

Nader Pouratian

Lead sponsor

University of Texas Southwestern Medical Center

Sponsor institution